CytoNiche was founded in 2018 by Professor Du Yanan and his two former students, Dr. Liu Wei and Dr. Yan Xiaojun, pioneers in microtissue engineering. Their decade-long research at Tsinghua University focused on a revolutionary concept: designing biomimetic 3D porous microcarriers—essentially creating "homes for cells" in vitro. By integrating micro-/nanotechnology, material science, and bioengineering, they engineered injectable, elastic micro-scale biomaterials that encapsulate cells like "smart spacesuits," enabling non-invasive, targeted delivery and enhancing cell survival for advanced therapies.
This breakthrough not only improved cell therapy efficacy but also transformed drug development by creating 3D in vitro disease models. Yet, as we ventured deeper into cell and gene therapy (CGT), a critical gap emerged: the lack of scalable, standardized manufacturing solutions to bring these life-saving therapies to patients affordably.
From Scientific Insight to Industrial Innovation
Driven by this challenge, we evolved from innovators in cell delivery to architects of industrial-scale CGT manufacturing. Our 3D FloTrix technology reimagines cell culture by designing 3D dissolvable porous microcarriers—3D TableTrix and 3D RecomTrix (xeno-free)—that act as "apartments" for cells. Anchoring to these biomimetic scaffolds, stem cells thrive in bioreactors, achieving unprecedented expansion efficiency while maintaining therapeutic potency.
This technology marked a paradigm shift: transitioning from lab-scale experiments to automated, closed-system biomanufacturing. By minimizing manual handling, contamination risks, and facility costs, we unlocked the potential for industrialized, sustainable CGT production.
Our Dedications Today
Today, CytoNiche stands at the forefront of CGT manufacturing innovation.
Pioneering Milestones:
Powered China’s first approved stem cell drug (January 2, 2025) and are enabling over 20 pipelines globally.
Global Collaboration:
Partnering with biotechs in Singapore, Southeast Asia, the U.S., and Europe to redefine cell therapy scalability.
End-to-End Solutions:
From microcarrier design to bioreactor-based 3D cell mass production, we deliver turnkey systems tailored for CGT industrialization.
The Journey of CytoNiche
Architect for Cells -Expert in 3D Manufacturing of High Quality Cells
2025
Stem cell drug manufactured by 3D FloTrix technology was approved on market
China's first stem cell drug was approved for market on 2 Jan 2025 and CytoNiche's 3D FloTrix technology supported the manufacturing of this iconic drug.
2024
3D RecomTrix Recombinant Collagen Microcarriers Launched
Animal-origin free, xeno-free recombinant collagen-based microcarriers, 3D RecomTrix, were successfully developed and launched on market.
2023
3D FloTrix Technology & Product Chain for Cell Mass Manufacturing Completed & Launched
CytoNiche completed development and launching of product series along the entire process chain of 10 billion cell/batch manufacturing, including 3D TableTrix microcarriers, 3D FloTrix Digest, 3D FloTrix vivaSPIN series of cell culture systems, 3D FloTrix vivaPREP series of cell processing systems & 3D FloTrix vivaPACK & vivaFILL fill&finish systems.
2021
GMP-grade 3D TableTrix Microcarriers Registered on DMF
CytoNiche's GMP-grade 3D TableTrix Microcarriers successfully registered under Type IV & Type II DMF (U.S. FDA): 037798 & 035481
